Meningioma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Meningioma Pipeline Insight 2025' report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Meningioma pipeline landscape. It covers the Meningioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Meningioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Meningioma Pipeline. Dive into DelveInsight's comprehensive report today! @ Meningioma Pipeline Outlook
Key Takeaways from the Meningioma Pipeline Report
In May 2025, European Organisation for Research and Treatment of Cancer - EORTC conducted a LUMEN-1 trial will investigate in a prospective randomized trial the efficacy of the precision medicine "theranostic" concept of combining diagnostic patient selection using PET-based molecular imaging and target-specific therapeutic intervention using a systemically administered radioligand.
In May 2025, Baptist Health South Florida announced a phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma.
DelveInsight's Meningioma Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Meningioma treatment.
The leading Meningioma Companies such as NX Development Corp., Clarity Pharmaceutical Ltd., Bristol-Myers Squibb, Biosynthema Inc., and others.
Promising Meningioma Pipeline Therapies such as Nivolumab, Cabozantinib, Abemaciclib, SOM230C, Bevacizumab, 177Lu-DOTATATE, Pembrolizumab and others.
Stay ahead with the most recent pipeline outlook for Meningioma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Meningioma Treatment Drugs
Meningioma Emerging Drugs Profile
Gleolan: NX Devolopment Corp
NX development corp.'s drug, Gleolan also known as Aminolevulinic acid is an orally administered small molecule in development for the treatment and real time detection of meningioma. Gleolan is a prodrug that is metabolized intracellularly to form the fluorescent molecule Protoporphyrin IX (PpIX). The exogenous application of ALA leads to a highly selective accumulation of PpIX in tumor cells. Following excitation with blue light. It is a photosensitizer molecule which can utilize the energy to induce photochemical reactions to produce lethal toxic agents; ultimately results in cell death and tissue destruction.
Nivolumab: Bristol-Myers Squibb
Bristol-Myers Squibb 'breakthrough' drug nivolumab is currently being evaluated for the treatment of Meningioma and has demonstrated good safety and efficacy profile in phase II trials. Nivolumab is a human immunoglobin (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks the interaction with PD-L1 and PD-L2, releasing anti-tumor response.
The Meningioma Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Meningioma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Meningioma Treatment.
Meningioma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Meningioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Meningioma market
Explore groundbreaking therapies and clinical trials in the Meningioma Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Meningioma Drugs
Meningioma Companies
NX Development Corp., Clarity Pharmaceutical Ltd., Bristol-Myers Squibb, Biosynthema Inc., and others.
Meningioma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Subcutaneous
Intravenous
Oral
Intramuscular
Molecule Type
Meningioma Products have been categorized under various Molecule types such as
Small molecules
Natural metabolites
Monoclonal antibodies
Product Type
Unveil the future of Meningioma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Meningioma Market Drivers and Barriers
Scope of the Meningioma Pipeline Report
Coverage- Global
Meningioma Companies- NX Development Corp., Clarity Pharmaceutical Ltd., Bristol-Myers Squibb, Biosynthema Inc., and others.
Meningioma Pipeline Therapies- Nivolumab, Cabozantinib, Abemaciclib, SOM230C, Bevacizumab, 177Lu-DOTATATE, Pembrolizumab and others.
Meningioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Meningioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Meningioma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Meningioma Companies, Key Products and Unmet Needs
Table of Contents
Introduction
Executive Summary
Meningioma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Meningioma – DelveInsight's Analytical Perspective
In-depth Commercial Assessment
Meningioma Collaboration Deals
Late Stage Products (Phase III)
Gleolan: Nx Development Corp.
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Nivolumab: Bristol-Myers Squibb
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Drug profiles in the detailed report…..
Inactive Products
Meningioma Key Companies
Meningioma Key Products
Meningioma- Unmet Needs
Meningioma- Market Drivers and Barriers
Meningioma- Future Perspectives and Conclusion
Meningioma Analyst Views
Meningioma Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
5 hours ago
- National Post
Dakota Johnson Named Global Brand Ambassador for Roberto Coin: Award-Winning Actress and Advocate Stars in New Jewelry Campaign
Article content NEW YORK — Roberto Coin, the renowned Italian maison known for its sophisticated design, romance, and impeccable craftsmanship, proudly announces actress and advocate Dakota Johnson as its new Global Brand Ambassador. Article content Article content This landmark partnership ushers in a dynamic new chapter for Roberto Coin, highlighting the brand's continued evolution through bold storytelling and artistry. A celebrated actress with a career spanning over two decades and a vocal advocate for mental health awareness, Johnson embodies Roberto Coin's philosophy of turning life's moments into extraordinary expressions of beauty, passion, and purpose. Article content Starting in June 2025 and running through May 2027, Johnson will star in a stunning new global campaign photographed by the legendary Craig McDean. Set against the breathtaking backdrop of Venice, the campaign captures the fusion of classic Italian beauty and contemporary elegance that defines Roberto Coin. Article content Venice serves as both the inspiration and the soul of this campaign. For Roberto Coin, the brand's founder, the connection to this iconic city is deeply personal. Born in Venice, its essence has profoundly shaped his creativity over the years. The city's rich history, majestic architecture, and vibrant artistic culture have long influenced his designs and inspired many of his collections. As such, Venice becomes the perfect backdrop and muse for this new campaign, a city of timeless beauty that perfectly mirrors the brand's elegance. Article content The campaign, featuring video and still photography, highlights Dakota wearing pieces from the brand's most iconic collections: Love in Verona, Venetian Princess, Navarra, Obelisco, Tiaré, and Cobra. Article content Released in two phases, the campaign's first half will launch in June, with the second installment debuting in May 2026. The full campaign will run through May 2027 across global platforms. Article content 'I've always believed that jewelry tells a story—of who you are, where you've been, and what you love,' said Dakota Johnson. 'Roberto Coin's pieces are full of depth and meaning, and I'm honored to help bring that spirit to life through this collaboration. There's romance, strength, and bold femininity in every design.' Article content In addition to the campaign, Johnson will make global appearances and participate in creative initiatives, helping share the Roberto Coin story with a new generation. Article content 'Dakota Johnson is a true original. I love her expressions—an artist with authenticity, depth, and a unique ability to connect,' said Roberto Coin, Founder and Creative Director. 'We are proud to welcome her to the Roberto Coin family and to collaborate on a campaign that speaks to the heart of who we are.' Article content Roberto Coin has been an icon in the jewelry industry for nearly 50 years. His designs include his signature collections like Appassionata, Animalier, Pois Moi and the current iconic Venetian Princess Collection. His collection is available in over 60 countries, in 200 points of sales and over 20 owned or franchise boutiques worldwide. Since 1977, Venetian jewelry designer Roberto Coin has devoted his life to a passion for innovative design, based on a deep knowledge of Italian art and craftsmanship tradition. Finding inspiration in the most unlikely of places, experimenting with light, texture, color, and pattern, Coin's style is ever evolving. His diverse collection, designed to fit every woman's uniqueness is defined by a common thread – a thoughtful balance of elegance and creativity. Included in every piece of Roberto Coin jewelry is his signature ruby. The ruby symbolizes peace, prosperity and happiness and is a special wish from the designer. Article content The distribution in North America is owned and operated by Watches of Switzerland Group, a leading luxury watch and jewelry retailer known for its prestigious portfolio of brands and commitment to exceptional service and client experience. Article content Article content Article content Article content Article content Article content
CBC
15 hours ago
- CBC
How a financial columnist coined 'TACO' to describe Trump's tariffs flip-flops
Wall Street has a new buzzword: TACO. But it's not about food — it's a tongue-in-cheek acronym directed at U.S. President Donald Trump's approach to trade policy. TACO stands for "Trump Always Chickens Out," a phrase coined by Financial Times columnist Robert Armstrong in a May 2 opinion piece. The term refers to Trump's pattern of announcing steep tariffs only to backpedal in the face of market turmoil. Most recently, on May 26, Trump postponed a planned 50 per cent tariff on European imports until July. Just two weeks earlier, on May 12, he put a 90-day freeze on proposed 145 per cent tariffs on Chinese goods. Both decisions came in response to sharp market reactions to rising trade tensions. The term made its way to the White House briefing room this week. During a press event on Wednesday, a reporter asked Trump directly about the TACO label. "You call that chickening out?" Trump responded. "It's called negotiation." He added, "Don't ever say what you said. That's a nasty question." Armstrong spoke with As It Happens host Nil Köksal about how he came up with the term and his thoughts on Trump's response. Here is part of their conversation. Was this the dream when you came up with "TACO," that it would not only be read around the world, but make it to an Oval Office press conference? It's not the dream, it's the nightmare. The thing about Trump chickening out is that it's good. Trump's tariff policies are very bad and destructive, right? When I talk about TACO and Trump chickening out, I'm like, "There's this good thing happening where he doesn't follow through on these bad ideas." I don't think this is gonna happen, but I have this slight worry that now he knows the phrase, and it's banging around in his head, he'll stop chickening out, which is exactly the outcome I don't want. How did this phrase "Trump Always Chickens Out" pop into your head? For the Financial Times, I write this newsletter every day and we were just observing this phenomenon where Trump would make a very loud threat about tariffs, and markets — stock markets, bond markets — would panic and then a day or a week would pass, and Trump would take it back, almost without any prompting whatsoever, and the markets would rebound. This happened with electronics and it happened with the Liberation Day reciprocal tariffs and it happened recently with the Europe 50 per cent tariff. So eventually, you're writing about the stuff all the time, and you just need a tagline so you don't have to explain what you're talking about every time. I was just like trying different things and TACO kind of popped into my mind, possibly because I was hungry, but possibly because it sounds a little bit [like] something like the president would make up himself. It's the kind of petty jive that he sort of likes, and it also has a slightly Mexican flavour to it, which is very funny in the case of this president who's obsessed with the border. Trump as you have heard … does not agree. He thinks these threats are a great negotiating tool. He says China and Europe are, [in] his words, begging for a deal. How do you respond? The first point is, this is a serious enough point. It is a classic principle of negotiation that you go in with a very high ask, and that anchors the conversation at that high number, and so it's easier to come to a compromise that's closer to you, so fair enough, that's part of how you negotiate. What's weird in Trump's case is that he makes his concessions before the other side has even had a chance to talk, so I don't really understand what the strategy is. Trump rails at 'TACO' buzzword mocking his tariff flip-flops 20 hours ago Duration 3:02 It's like, the least bit of economic or market pressure gets put on him, even before negotiations begin, and he just immediately wilts. What this says to me is, Trump likes tariffs on TV, but in real life, he's not really prepared to sacrifice that much, in terms of popularity, or political capital in order to get these policies through. His supporters, or certain segments of the population will only hear the first thing he says or see the … poster board he was holding up at that one news conference and whatever happens after that day or after those comments, they will remember that he appeared tough to them. There's a fantastic irony here, which is politically this made the recent intervention of the courts and blocking him and all the trouble he's having getting these tariffs through might be politically ideal for him in the following sense. The tariffs, if they'd gone through, in my view, would have been an economic disaster, and it would have been his economic disaster. If the courts or political opposition or any unknowing journalists or anybody else manages to stop him from doing this stuff, then he gets to say, "I tried to give you these miraculous tariffs, the woke court stopped me, and I'm still your guy."
CBC
16 hours ago
- CBC
Who is the next James Bond? It's anyone's guess. But a luxury watchmaker just shifted the odds
The rumour mill is both shaken and stirred at the prospect of the next James Bond star being inadvertently — maybe — leaked. Speculation has been swirling online in recent days that British actor Aaron Taylor-Johnson, the star of films like 2024's Kraven the Hunter and the 2022 hit Bullet Train, is poised to take on the role of the world's most beloved and admired spy after Swiss watchmaker Omega announced the 34-year-old is its new global brand ambassador. Both Taylor-Johnson and Omega shared images over the past week of him sporting its watches and touring its factory. Why is that a big deal you ask? The luxury brand has adorned Agent 007 for 30 years, worn in films and ads by recent Bond actors Pierce Brosnan and Daniel Craig, which is why fans and oddsmakers — yes, you can place your bets on the next Bond — took note of the Taylor-Johnson/Omega marriage. While Taylor-Johnson has been on several lists of potential actors who could portray the suave and sexy super spy in the franchise's 26th instalment, Bond is a fixture in popular culture like few others and predicting who and what's next for him is somewhat of a sport in its own right. And because it's the "off season" for fans right now, it's the perfect time to watch for any indication of a big announcement, says Lisa Funnell, a Hamilton-based scholar and author who has been researching Bond books, film and culture for more than 20 years. It's been nearly four years since the last film of the Craig era, No Time to Die, was released — which was delayed more than a year due to COVID-19 pandemic lockdowns. The longest period between Bond films was six years, after Roger Moore's last turn in 1989's Licence to Kill and Brosnan taking the torch in 1995's GoldenEye. "I think until we get a full announcement coming at us, we're not going to know. We're only going to be speculating, which is kind of fun," she said. The perfect Bond Taylor-Johnson has a lot going for him, says British writer and and Bond aficionado Mark O'Connell, adding that he has met the actor and is cheering for him. "He's definitely in my top three or five Bond contenders," he said. "He looks great on screen. The camera loves him. Maybe the box office doesn't yet, Kraven didn't do so well, but the box office and the magazine covers... really love him." But O'Connell isn't taking the Omega partnership as a sign of anything, pointing to the fact another contender, Academy Award-nominated Irish actor Barry Keoghan, is also affiliated with the brand. It may also be worth noting that Taylor-Johnson was sporting an Omega Speedmaster watch in the photos the company posted on social media, while Keoghan was sporting one of its Seamaster series, which is the line that Bond wore in the last nine films. But, moving on. O'Connell thinks Taylor-Johnson stands a solid chance not just because of his looks and acting chops but because he's not too big of a star yet. He says the franchise has typically casts actors who aren't household names. Both he and Funnell agree that a superstar like Superman franchise heartthrob Henry Cavill, whose name has been tossed around and who certainly has the look, is just too big for Bond. That's something that could also count out someone like Jonathan Bailey, whose star is soaring with the blockbuster Wicked and the upcoming Jurassic World: Rebirth. One thing O'Connell believes is a sure bet is that the next Bond will be British (sorry Canadian, American and Australian actors). Bond enters the Amazon era The Hollywood Reporter predicted in December that the next Bond would be Josh O'Connor, known for last year's Challengers and his Emmy-winning turn as Prince Charles in the Netflix series The Crown, suggesting longtime series producer Barbara Broccoli "has always led from the gut, not caved to popular opinion." But here's the thing: She's no longer has creative control of the franchise her family has helmed since its inception in the 1960s. Amazon and MGM Studios are now in charge (MGM owns the rights to the film franchise, Amazon now owns MGM), after striking a deal earlier this year and has already tapped Amy Pascal and David Heyman to produce the film known, for the moment, as Bond 26. That shift left a lot up in the air, says Funnell. "We're entering into brand-new territory," she said. The new producers, she says, could go in a new direction that might not necessarily "fall in step with all the rules that the Bond franchise has had up to this point." Funnell suggests Amazon has an advantage by having so much streaming data and information about what's being watched by which demographics, and that could help inform its decisions of both what kind of star it wants — possibly someone who will attract younger audiences — and the style of Bond movie it makes. She says Amazon also has to take into account the success of other Bond-esque films that have filled the void since the last feature, including two Mission: Impossible movies. She's personally keen to see a return to a more classic style; movies more about the missions and lots more of the gadgets. "I want things that explode, exploding pens, whatever," she said — rather than the more style-driven and and "deeply personal" storylines of the Craig era. O'Connell doesn't think Amazon will shake things up too much because it's "really keen to get it right." As for a big star reveal, he says it likely won't happen until the next writer and director are announced, noting many eyes have been on Oscar-winning Mexican director Alfonso Cuarón (Roma, Gravity). But that, too, is speculation. WATCH | Bond creator Ian Fleming speaks with CBC in 1964: Ian Fleming: a 1964 interview with the brain behind Bond 61 years ago Duration 27:16 Explorations airs an intimate chat with James Bond creator Ian Fleming in his Jamaican hideaway Aired on the CBC-TV program Explorations on Aug. 17, 1964.
